CUI JINGRONG JEAN (Chief Scientific Officer) sold 5.1% of their position (44K shares) of TURNING POINT THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.80M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−7.10K
Price / share
$41.61
Trade value
$295.43K
% of position
Common Stock
Shares
−8K
Price / share
$42.42
Trade value
$339.36K
% of position
Common Stock
Shares
−3.40K
Price / share
$43.33
Trade value
$147.32K
% of position
Common Stock
Shares
−4.70K
Price / share
$40.02
Trade value
$188.09K
% of position
Common Stock
Shares
−6.80K
Price / share
$40.61
Trade value
$276.15K
% of position
Common Stock
Shares
−2.40K
Price / share
$41.50
Trade value
$99.60K
% of position
Common Stock
Shares
−3.20K
Price / share
$42.86
Trade value
$137.15K
% of position
Common Stock
Shares
−1.40K
Price / share
$43.72
Trade value
$61.21K
% of position
Common Stock
Shares
−2.60K
Price / share
$34.96
Trade value
$90.90K
% of position
Common Stock
Shares
−1.82K
Price / share
$36.07
Trade value
$65.68K
% of position
Common Stock
Shares
−1.88K
Price / share
$36.94
Trade value
$69.37K
% of position
Common Stock
Shares
−701.00
Price / share
$37.91
Trade value
$26.57K
% of position
Net shares
−44K
Net value
-$1.80M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 3/10/2020 | S · Sale | −7.10K | $41.61 | $295.43K | 0.8% | 869.38K | 862.28K |
| Common Stock Indirect | 3/10/2020 | S · Sale | −8K | $42.42 | $339.36K | 0.9% | 862.28K | 854.28K |
| Common Stock Indirect | 3/10/2020 | S · Sale | −3.40K | $43.33 | $147.32K | 0.4% | 854.28K | 850.88K |
| Common Stock Indirect | 3/11/2020 | S · Sale | −4.70K | $40.02 | $188.09K | 0.6% | 850.88K | 846.18K |
| Common Stock Indirect | 3/11/2020 | S · Sale | −6.80K | $40.61 | $276.15K | 0.8% | 846.18K | 839.38K |
| Common Stock Indirect | 3/11/2020 | S · Sale | −2.40K | $41.50 | $99.60K | 0.3% | 839.38K | 836.98K |
| Common Stock Indirect | 3/11/2020 | S · Sale | −3.20K | $42.86 | $137.15K | 0.4% | 836.98K | 833.78K |
| Common Stock Indirect | 3/11/2020 | S · Sale | −1.40K | $43.72 | $61.21K | 0.2% | 833.78K | 832.38K |
| Common Stock Indirect | 3/12/2020 | S · Sale | −2.60K | $34.96 | $90.90K | 0.3% | 832.38K | 829.78K |
| Common Stock Indirect | 3/12/2020 | S · Sale | −1.82K | $36.07 | $65.68K | 0.2% | 829.78K | 827.96K |
| Common Stock Indirect | 3/12/2020 | S · Sale | −1.88K | $36.94 | $69.37K | 0.2% | 827.96K | 826.08K |
| Common Stock Indirect | 3/12/2020 | S · Sale | −701.00 | $37.91 | $26.57K | 0.1% | 826.08K | 825.38K |
| Total | −44K | -$1.80M | ||||||
Common Stock
IndirectCommon Stock
Direct| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 300K | Indirect |
| Common Stock | 1M | Direct |
| Total | 1.30M | 1M direct·300K indirect |